Yvonne Greenstreet Sells 6,979 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Key Points

• Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, sold 6,979 shares of the company's stock for approximately $3.16 million, marking an 11.04% decrease in her holdings.
• Alnylam's stock recently traded up 0.3%, reaching around $458.28, with a market capitalization of $60.07 billion.
• Analysts have raised their price targets for Alnylam Pharmaceuticals, with a consensus target of $405.33, reflecting strong expectations for the company's performance.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CEO Yvonne Greenstreet sold 6,979 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $3,163,371.33. Following the completion of the transaction, the chief executive officer owned 56,221 shares of the company's stock, valued at approximately $25,483,292.67. The trade was a 11.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Yvonne Greenstreet also recently made the following trade(s):

• On Monday, June 2nd, Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00.
• On Friday, May 30th, Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded down $13.17 during trading hours on Friday, hitting $454.38. The company's stock had a trading volume of 1,075,489 shares, compared to its average volume of 1,386,802. The company has a 50 day moving average of $360.65 and a 200 day moving average of $296.84. The stock has a market cap of $59.56 billion, a PE ratio of -183.96 and a beta of 0.25. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $469.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company's revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ALNY. Vanguard Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 1.8% in the second quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company's stock valued at $4,336,064,000 after acquiring an additional 240,534 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 0.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock valued at $1,192,988,000 after acquiring an additional 33,696 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Alnylam Pharmaceuticals by 5.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock valued at $946,466,000 after acquiring an additional 185,783 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Alnylam Pharmaceuticals by 3.3% in the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company's stock valued at $779,857,000 after acquiring an additional 75,936 shares during the last quarter. Finally, Orbis Allan Gray Ltd lifted its holdings in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after acquiring an additional 486,489 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALNY. Piper Sandler raised their price target on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Wolfe Research raised shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. Truist Financial started coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $385.00 target price for the company. Wall Street Zen upgraded Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Finally, Morgan Stanley boosted their price objective on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $405.33.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.